Cite
Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response
MLA
Taylor, David N., et al. “Development of VAX128, a Recombinant Hemagglutinin (HA) Influenza-Flagellin Fusion Vaccine with Improved Safety and Immune Response.” Vaccine, vol. 30, no. 39, Aug. 2012, pp. 5761–69. EBSCOhost, https://doi.org/10.1016/j.vaccine.2012.06.086.
APA
Taylor, D. N., Treanor, J. J., Sheldon, E. A., Johnson, C., Umlauf, S., Song, L., Kavita, U., Liu, G., Tussey, L., Ozer, K., Hofstaetter, T., & Shaw, A. (2012). Development of VAX128, a recombinant hemagglutinin (HA) influenza-flagellin fusion vaccine with improved safety and immune response. Vaccine, 30(39), 5761–5769. https://doi.org/10.1016/j.vaccine.2012.06.086
Chicago
Taylor, David N., John J. Treanor, Eric A. Sheldon, Casey Johnson, Scott Umlauf, Langzhou Song, Uma Kavita, et al. 2012. “Development of VAX128, a Recombinant Hemagglutinin (HA) Influenza-Flagellin Fusion Vaccine with Improved Safety and Immune Response.” Vaccine 30 (39): 5761–69. doi:10.1016/j.vaccine.2012.06.086.